Introduction:
Trans-catheter pulmonary valve therapy is an alternative to surgery for children and adult who have a failing surgically placed conduit for congenital heart defect like Tetralogy of Fallot (TOF), Pulmonary Atresia, Transposition of Great Arteries (TGA), Double Outlet Right Ventricles (DORV) etc. Conduits are considered as not functioning when it has become stenotic (RVOT gradient greater more than or equal to 35 mm Hg) or regurgitant (moderate or more severe regurgitation) 1 . Percutaneous pulmonary valve implantation (PPVI) is a new treatment option in patients with RVOT conduit dysfunction. Conduit size of the individual must be equal to or greater then 16 mm in diameter to qualify for the procedure. Melody ® is a replacement pulmonary heart valve used for above purpose.
The objective of PPVI is to prolong the life span of right ventricle to pulmonary artery conduit thus postponing open heart surgery 2-4 .
Early follow up result of the procedure showed significant reduction of RV pressure and RVOT gradient. The most common complication which may be encountered in follow up is stent fracture 5. So PPVI has the potential to become the standard procedure in the treatment of dysfunctional conduit. We report the first case of PPVI in South Asia where a Melody ® with 20 mm ensemble was used in 11 years old boy successfully.
Case report:
J, an eleven years old boy was diagnosed as Tetralogy of Fallot (TOF) with absent left pulmonary artery at the age of two years. He had his first surgery on 27 th July 2007 in Narayana Hridayalaya, Bengalore, India which was a trans-atrial repair.
During his follow up, some residual and new problems were observed in echocardiography, chest x-ray and electrocardiography. Patient was symptomatic also in the form of exert ional dyspnoea.
So cardiac catheterization was repeated on 3 rd September 2008 and severe right pulmonary artery (RPA) origin stenosis, severe tricuspid regurgitation (TR) and severe pulmonary regurgitation (PR) was noticed.
He was referred again to same centre of India for Redo surgery. Aortogram was done to assess coronary artery arrangement.
RVOT angiogram was done to assess morphology of RVOT and conduit, and severity of stenosis. Pulmonary angiogram was done to look for severity of regurgitation.
A 14F Mullin sheath was guided over a landerquest wire into PA and dilator was removed. Balloon dilatation of conduit was done with 22 mm high pressure balloon.
A CP stent of 39 mm length was placed inside conduit to cover the calcified area.
Another 42 mm CP stent was again implanted to cover the whole length of conduit and BIB balloon of 20 mm was used for expansion of stent.
The Melody valve was washed in 3 saline baths for 5 minutes each to clear the gluteraldehyde preservative.
The Ensemble of 20 mm was flushed and the balloons were de aired.
The venous access was dilated with dilators upto 22 mm.
The valve was crimped on the balloon catheter of the delivery system carefully to orientate it in the direction of blood flow and finally covered with the outer sheath.
The valve over the ensemble was forwarded over the wire to the site of implantation
The valve was uncovered at the optimum site. Check angiography was performed through side port to confirm the site of implantation. Dilatation of inner balloon was followed by dilatation of outer balloon to deploy valved stent.
The delivery system was pulled out carefully keeping the guide wire in position.
Repeat hemodynamic assessment was performed and angiography was done at pulmonary artery.
No PR or PS was noticed. Haemostasis was achieved by applying a tie with silk. Patient was shifted to cardiac ICU after extubation.
Echocardiography on next morning showed well functioning Melody valve with negligible residual The surgical correction of above conditions often includes the creation of an artificial right ventricle (RV) to pulmonary artery (PA) connection by RV to PA conduit. After repair, over time, these conduits are prone to develop valve dysfunction leading to pulmonary regurgitation (PR), stenosis (PS), thrombosis, infections and calcifications 9, 10 . Chronic PR after relief of RV out flow tract obstruction can lead to RV 11 dilatation, biventricular dysfunction, heart failure symptoms, arrhythmia and sudden death 11 . There is a very close relationship between the degree of PR and RV volumes which was confirmed by many studies [11] [12] [13] [14] [15] . Tetralogy of Fallot is the most common from of cyanotic congenital heart disease with frequency of 06-08 per 1000 live birth 16 . Total surgical repair was available for last 50 years with favorable outcome in most cases. But surgical repair of tetralogy of Fallot (TOF) may results in many anatomic and functional abnormalities. In the majority of patients in follow up period most common problems are pulmonary regurgitation and conduit stenosis. Though RV volume overload due to severe PR tolerated over years, there is now evidence that the compensatory mechanisms of the right ventricular myocardium ultimately fail and that if the load is not eliminated or reduced, the dysfunction might be irreversible 17 . As a result early pulmonary valve replacement is recommended in many centers.
Pulmonary valve replacement can be performed electively with little risk and may improve symptoms of right ventricular failure and provide excellent midterm survival in above mentioned group of patient 18 .
Our patient was a case of TOF with absent left pulmonary artery who had surgery on two occasions earlier, than pulmonary valve replacement was decided for conduit dysfunction.
Indications for PPVI are 19 • Severe pulmonary regurgitation.
• Residual RVOT obstruction>30 mm Hg.
• Electrocardiographic evidence of QRS prolongation >180 milliseconds.
Candidates for PPVI must also fulfill the anatomic requirements necessary for safe anchoring of the percutaneous valve: So conduit provide such properties pulmonary stenosis (PPG 15 mm Hg) and no PR. Patient was discharged after 03 days with an advice to continue Aspirin for 06 months and follow up after 04 weeks.
Discussion:
Congenital cardiac defect involving the right ventricular outflow tract (RVOT) require initial surgical interventions as early as the neonatal period. These defect may include severe pulmonic stenosis, pulmonary Atresia with or without ventricular septal defect, for PPVI. In contrast native or patched out flow after TOF repair tends to be dilated and remain dynamic and therefore do not provide a secure implantation site 19 .
In our case we have used Melody valve which was approved by Food and Drug Administration (FDA) in USA in January 2010.
Procedure related risks are stent fracture, embolization of valve, acute coronary compression etc. Coronary compression demands urgent surgical intervention.
Experience of PPVI in two centre over 100 patients showed excellent result regarding reduction of RVOT gradient and PR 20 .
Outcome of pulmonary valve replacement in 170 patients with chronic PR after relief of ROVT obstruction was also found acceptable in another study 11 .
Early result from the US clinical trial on Melody transcatheter pulmonary valve also recommends the procedure as safe and effective one 21 .
A multicentre survey was performed by Italian society of pediatric cardiology (SICP) to analyze the data of patients treated by Melody Medtronic valve 22 . This study result showed that the procedure is safe and successful. Major concerns are related to the occurrence of stent fracture and bacterial endocarditis.
Conclusion:
Percutaneous pulmonary valve implantation (PPVI) is a new treatment option in patient with RVOT conduit regurgitation and stenosis. Early results following PPVI have shown a significant reduction in right ventricular pressure and RVOT gradient. The most common complication of PPVI is stent fracture or PR in the context of endocarditis. We got excellent result in our first case. So PPVI has the potential to become the standard procedure in the treatment of dysfunctional conduit and will be easy to procure if price is considered for the developing countries.
